Filing Flows › Medtronic (MDT) › Guidance & outlook
Medtronic (MDT) guidance and outlook
Medtronic's 10-Q filed Sep 3, 2026 makes 10 forward-looking statements, 2 of them new and 12 no longer said since the filing before.
Guidance and outlook
Forward-looking statements, 10-Q filed Sep 3, 2026
- In addition to the macroeconomic and geopolitical factors described in the Executive Level Overview, looking ahead, we expect Cardiovascular could be affected by the following:
- In addition to the macroeconomic and geopolitical factors described in the Executive Level Overview, looking ahead we expect Neuroscience could be affected by the following:
- In addition to the macroeconomic and geopolitical factors described in the Executive Level Overview, looking ahead we expect Medical Surgical could be affected by the following:
- new · The impact for both the three months ended July 31, 2026 and July 25, 2025 was not material, nor does the Company expect the provisions of the Act to materially impact the remainder of fiscal year 2027 or beyond.
- We do not expect the S&P and Moody's ratings to have a significant impact on our liquidity or future flexibility to access additional liquidity given our balance sheet, Credit Facility, and related commercial paper programs.
- new · We believe our off-balance sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position, and/or cash flows.
- The Company plans to complete the separation of its Diabetes Business within this fiscal year.
- The test for impairment of goodwill requires us to make several estimates related to projected future cash flows to determine the fair value of the goodwill reporting units.
- We use estimates that are consistent with the highest and best use of the assets based on a market participant's view of the assets being evaluated.
- Our forecast of future cash flows is based on estimates of projected revenue and projected earnings, based primarily on pricing, raw material costs, market share, industry outlook, general economic conditions and strategic actions to improve our earnings.
Medtronic's latest quarter
Medtronic, Q1 FY27: revenue $9.8B (+14% year over year), operating margin 18.1%, net earnings $1.5B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Questions
What does Medtronic expect?
The impact for both the three months ended July 31, 2026 and July 25, 2025 was not material, nor does the Company expect the provisions of the Act to materially impact the remainder of fiscal year 2027 or beyond. We believe our off-balance sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position, and/or cash flows.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.